What is Genialis, Inc?
Genialis, Inc. is a precision oncology firm dedicated to overcoming critical challenges in cancer treatment, including patient response variability and high clinical trial failure rates. By leveraging advanced AI models and a sophisticated multiomics data infrastructure, the company's proprietary Genialis Supermodel provides crucial therapeutic intelligence across the entire drug development lifecycle. This technology empowers enhanced patient stratification and aims to significantly improve the success rates of oncology clinical trials, positioning Genialis at the forefront of AI-driven pharmaceutical innovation.
How much funding has Genialis, Inc raised?
Genialis, Inc has raised a total of $15.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$13M
Angel/Seed (2017): $2.3M with participation from First Star Ventures and Redalpine
Series A (2023): $13M led by Taiwania Capital, Debiopharm, and First Star Ventures
Key Investors in Genialis, Inc
Debiopharm
Debiopharm Investment, the investment arm of Debiopharm Group, focuses on safeguarding capital and generating financial returns for its subsidiaries, with interests in finance, real estate, and private equity.
First Star Ventures
First Star Ventures is an investment firm that supports technical founders in advanced technologies like AI/ML and techbio, leveraging its network to help hard computing tech startups scale rapidly.
Redalpine
redalpine is a venture capital firm established in 2006, specializing in software and science, aiming to empower game changers and disrupt industries through strategic and hands-on support for highly technical companies.
What's next for Genialis, Inc?
The recent major strategic investment signals a strong validation of Genialis's technological approach and market potential within the competitive precision oncology landscape. This capital is anticipated to fuel further development of their AI platforms, expand research and development initiatives, and potentially broaden strategic partnerships within the pharmaceutical and biotechnology sectors. Genialis is poised to accelerate its pipeline and solidify its position as a leader in AI-powered drug discovery and development, aiming to bring novel cancer therapies to patients more efficiently.
See full Genialis, Inc company page
